Contains Nonbinding Recommendations

Draft Guidance on Telmisartan

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Telmisartan

Form/Route: Tablets/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 80 mg
   Subjects: Healthy males and nonpregnant females, general population
   Additional Comments: The subjects should remain in a comfortable recumbent position for up to 8 hours after dosing and remain under medical surveillance for up to 12 hours after dosing. Before they are allowed to ambulate, they should sit up with legs in a dependent position for one minute prior to standing up. While standing immobile, they should be closely observed for blood pressure changes and/or orthostatic symptoms, including nausea, dizziness, or faintness for at least three minutes.

   Applicants may consider using a reference-scaled average bioequivalence approach for this drug product. If using this approach, the applicant should provide evidence of high variability in the bioequivalence parameters AUC and/or Cmax (i.e., within-subject variability ≥ 30%). For general information on this approach, please refer to the Individual Products Bioequivalence Recommendations Guidance for Progesterone Capsules.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 80 mg
   Subjects: Healthy males and nonpregnant females, general population.
   Additional Comments: Please see additional comments above

Analytes to measure (in appropriate biological fluid): Telmisartan in plasma

Bioequivalence based on (90% CI): Telmisartan

Waiver request of in-vivo testing: 20 mg and 40 mg based on (i) acceptable bioequivalence studies on the 80 mg strength, (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.

Recommended May 2008; Revised Oct 2010
Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended May 2008; Revised Oct 2010